Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial
Premium

Portfolio: Strides Merger Pushes it Up, Time for an Options Play

On the portfolio we have some quick news.

Strides Arcolab: Buys Shasun, Gets a 50% Return on Stelis investment Strides will merge with Shasun Pharma, in an all stock deal. Shasun is listed on the BSE/NSE and its shareholders will get 5 shares of Strides for every 16 shares in Shasun. This is an approximately 33% dilution - in the sense, that the merged entity will have 74% Strides shareholders and 26% Shasun.

Shasun has . . .

Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial